A Phase 2 Safety Study of ATI-502 Topical Solution in Subjects With Moderate to Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2019
Price : $35 *
At a glance
- Drugs ATI 502 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Aclaris Therapeutics
- 08 Aug 2019 Results presented in an Aclaris Therapeutics media release.
- 10 May 2019 Status changed from active, no longer recruiting to completed.
- 18 Mar 2019 Status changed from recruiting to active, no longer recruiting, according to an Aclaris Therapeutics media release.